Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with Lewis Y-expressing epithelial tumors Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antigens, Tumor-Associated, Carbohydrate
  • Antineoplastic Agents
  • Doxorubicin
  • Immunotoxins
  • Neoplasms, Glandular and Epithelial

abstract

  • BR96-Dox provides a unique strategy to deliver doxorubicin to Le(Y)-expressing tumor and was well tolerated at doses of 700 mg/m(2) every 3 weeks. BR96-Dox was not associated with the typical side-effect profile of native doxorubicin and can potentially deliver high doses of doxorubicin to antigen-expressing tumors. A phase II study in doxorubicin-sensitive tumors is warranted.

publication date

  • June 2000

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 10829049

Additional Document Info

start page

  • 2282

end page

  • 92

volume

  • 18

number

  • 11